Medicamen Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 06-12-2024
- Paid Up Capital ₹ 10.00 Cr
as on 06-12-2024
- Company Age 2 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.42 Cr
as on 06-12-2024
About Medicamen Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 10.00 Cr.
The company currently has active open charges totaling ₹1.42 Cr.
Rahul Bishnoi, Ashwani Sharma, and Kamal Pahwa serve as directors at the Company.
- CIN/LLPIN
U24290DL2022PTC403121
- Company No.
403121
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Aug 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Medicamen Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Pahwa  | Managing Director | 12-Aug-2022 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rahul Bishnoi | Director | 12-Aug-2022 | Current |
| Ashwani Sharma | Director | 12-Aug-2022 | Current |
Financial Performance and Corporate Structure Insights of Medicamen Life Sciences.
Medicamen Life Sciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Medicamen Life Sciences?
In 2023, Medicamen Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Medicamen Biotech LimitedActive 30 years 11 monthsRahul Bishnoi and Ashwani Sharma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 19 Jan 2024 | ₹1.00 Cr | Open |
Hdfc Bank Limited Creation Date: 28 Jul 2023 | ₹4.19 M | Open |
How Many Employees Work at Medicamen Life Sciences?
Medicamen Life Sciences has a workforce of 84 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medicamen Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medicamen Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
